A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer

By Beardsley Emma  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1652-1659

Springer Publishing Company

Access to resources Recommend Favorite

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment

By Badrising Sushil   van der Noort Vincent   van Oort Inge M.   van den Berg H. Pieter   Los Maartje   Hamberg Paul   Coenen Jules L.   van den Eertwegh Alfons J. M.   de Jong Igle J.   Kerver Emile D.   van Tinteren Harm   Bergman Andries M.  

Cancer, Vol. 120, Iss. 7, 2014-04 ,pp. : 968-975

Blackwell Publishing

Access to resources Recommend Favorite

Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium

By Alva Ajjai  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 749-757

Springer Publishing Company

Access to resources Recommend Favorite

Phase II and Pharmacological Study of Oral Docetaxel Plus Cyclosporin A in Anthracycline Pre-Treated Metastatic Breast Cancer

By  

Current Clinical Pharmacology, Vol. 9, Iss. 2, 2014-05 ,pp. : 139-147

Bentham Science Publishers

Access to resources Recommend Favorite

Docetaxel: A Review of its Use for the First-Line Treatment of Advanced Castration-Resistant Prostate Cancer

By McKeage Kate  

Drugs, Vol. 72, Iss. 11, 2012-07 ,pp. : 1559-1577

Adis International

Access to resources Recommend Favorite